MX367082B - Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. - Google Patents

Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos.

Info

Publication number
MX367082B
MX367082B MX2015005481A MX2015005481A MX367082B MX 367082 B MX367082 B MX 367082B MX 2015005481 A MX2015005481 A MX 2015005481A MX 2015005481 A MX2015005481 A MX 2015005481A MX 367082 B MX367082 B MX 367082B
Authority
MX
Mexico
Prior art keywords
aureus
methods
treating
preventing
reducing
Prior art date
Application number
MX2015005481A
Other languages
English (en)
Spanish (es)
Other versions
MX2015005481A (es
Inventor
Sellman Bret
Huang Lei
Tkaczyk Christine
Hamilton Melissa
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2015005481A publication Critical patent/MX2015005481A/es
Publication of MX367082B publication Critical patent/MX367082B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2015005481A 2012-11-06 2013-11-05 Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. MX367082B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Publications (2)

Publication Number Publication Date
MX2015005481A MX2015005481A (es) 2016-01-14
MX367082B true MX367082B (es) 2019-08-05

Family

ID=50685101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005481A MX367082B (es) 2012-11-06 2013-11-05 Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos.

Country Status (13)

Country Link
US (3) US9845348B2 (enExample)
EP (1) EP2928490B1 (enExample)
JP (2) JP6506172B2 (enExample)
KR (3) KR20210083389A (enExample)
CN (2) CN112316135A (enExample)
AU (2) AU2013341421A1 (enExample)
BR (1) BR112015010126B1 (enExample)
CA (1) CA2890385C (enExample)
ES (1) ES2912267T3 (enExample)
MX (1) MX367082B (enExample)
RU (1) RU2661406C2 (enExample)
SG (2) SG11201503231YA (enExample)
WO (1) WO2014074470A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
US10597439B2 (en) 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
JP6506172B2 (ja) * 2012-11-06 2019-04-24 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
US11155606B2 (en) 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
US12264194B2 (en) 2019-03-13 2025-04-01 Medimmune, Llc Decreasing Staphylococcus aureus infections in colonized patients
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053235A1 (en) * 2006-06-12 2009-02-26 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
WO2011008939A2 (en) * 2009-07-16 2011-01-20 Medical College Of Georgia Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
CA2825770A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
BR112013020086B1 (pt) * 2011-02-08 2020-12-08 Medimmune, Llc Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
JP6506172B2 (ja) * 2012-11-06 2019-04-24 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
KR102272744B1 (ko) 2021-07-06
JP6926138B2 (ja) 2021-08-25
SG10201703677VA (en) 2017-06-29
EP2928490A4 (en) 2016-11-02
KR20150092738A (ko) 2015-08-13
SG11201503231YA (en) 2015-05-28
AU2018236849A1 (en) 2018-10-18
CN112316135A (zh) 2021-02-05
BR112015010126A2 (enExample) 2017-08-22
JP6506172B2 (ja) 2019-04-24
BR112015010126B1 (pt) 2022-11-01
US10759849B2 (en) 2020-09-01
US20190002540A1 (en) 2019-01-03
WO2014074470A1 (en) 2014-05-15
JP2019142888A (ja) 2019-08-29
CA2890385C (en) 2022-07-12
RU2015121617A (ru) 2016-12-27
CA2890385A1 (en) 2014-05-15
ES2912267T3 (es) 2022-05-25
US9845348B2 (en) 2017-12-19
EP2928490A1 (en) 2015-10-14
JP2015536951A (ja) 2015-12-24
EP2928490B1 (en) 2022-03-30
US20160257733A1 (en) 2016-09-08
US20200109191A1 (en) 2020-04-09
AU2013341421A1 (en) 2015-06-04
US10457724B2 (en) 2019-10-29
HK1215173A1 (zh) 2016-08-19
CN104780934A (zh) 2015-07-15
MX2015005481A (es) 2016-01-14
RU2661406C2 (ru) 2018-07-16
AU2018236849B2 (en) 2020-05-21
KR20210083389A (ko) 2021-07-06
KR20200102533A (ko) 2020-08-31

Similar Documents

Publication Publication Date Title
MX2015005481A (es) Metodos para tratar enfermedades asociadas con s. aureus.
NZ709997A (en) Methods for treating conditions associated with masp-2 dependent complement activation
NZ630363A (en) Anti-kit antibodies and uses thereof
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
MX2015006681A (es) Formulaciones de vancomicina estabilizadas.
WO2013119716A8 (en) Compositions and methods for using csf1r inhibitors
UA115034C2 (uk) Імунокон'югат для застосування в лікуванні раку або запального порушення
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
MX2020009700A (es) Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso.
MX2022012083A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
MX352599B (es) Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
BR112015010125A2 (pt) Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
EP4516811A3 (en) Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
HK1200463A1 (en) Human antibodies to clostridium difficile toxins
PT2594588E (pt) Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para utilização em terapia
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
UA117097C2 (uk) Антитіло проти лігандів рецептора в1 брадикініну
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
GB201109238D0 (en) Antibodies
SG10201807059QA (en) Agents for influenza neutralization
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.

Legal Events

Date Code Title Description
FG Grant or registration